Triamcinolone Acetonide Suprachoroidal Injectable Suspension(Arctic Vision)

Tier C — Watch / trade

Clearside Biomedical Inc

Originator

2021

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：GR

Brand：ARCATUS, XIPERE

Indications (approved)：黄斑水肿, 葡萄膜炎

Regional status

Approved

2021-10-22

Discontinued

2017-01-31

China

Filed / under review

2025-01-27

Japan

Factories producing this API1

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

1 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Triamcinolone Acetonide Suprachoroidal Injectable Suspension(Arctic Vision)?

Approved indications include: 黄斑水肿, 葡萄膜炎.

When does the Triamcinolone Acetonide Suprachoroidal Injectable Suspension(Arctic Vision) patent expire?

No public expiry year is available for Triamcinolone Acetonide Suprachoroidal Injectable Suspension(Arctic Vision) yet; this page updates once verified.

How do I get a quote for Triamcinolone Acetonide Suprachoroidal Injectable Suspension(Arctic Vision) intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27